These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 11859684)

  • 1. Sex differences in drug metabolism: cytochrome P-450 and uridine diphosphate glucuronosyltransferase.
    Anderson GD
    J Gend Specif Med; 2002; 5(1):25-33. PubMed ID: 11859684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Genetic polymorphisms of drug metabolizing enzymes].
    Fujieda M; Yamazaki H; Kamataki T
    Gan To Kagaku Ryoho; 2002 May; 29(5):663-8. PubMed ID: 12040668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the substrate specificities of human liver cytochrome P450s 2C9 and 2C18: application to the design of a specific substrate of CYP 2C18.
    Minoletti C; Dijols S; Dansette PM; Mansuy D
    Biochemistry; 1999 Jun; 38(24):7828-36. PubMed ID: 10387023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo modulation of CYP enzymes by quinidine and rifampin.
    Branch RA; Adedoyin A; Frye RF; Wilson JW; Romkes M
    Clin Pharmacol Ther; 2000 Oct; 68(4):401-11. PubMed ID: 11061580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How useful is the "cocktail approach" for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo?
    Tanaka E; Kurata N; Yasuhara H
    J Clin Pharm Ther; 2003 Jun; 28(3):157-65. PubMed ID: 12795773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
    Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
    Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoreactivity to various human cytochrome P450 proteins of sera from patients with autoimmune hepatitis, chronic hepatitis B, and chronic hepatitis C.
    Miyakawa H; Kitazawa E; Kikuchi K; Fujikawa H; Kawaguchi N; Abe K; Matsushita M; Matsushima H; Igarashi T; Hankins RW; Kako M
    Autoimmunity; 2000; 33(1):23-32. PubMed ID: 11204250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of single-dose disulfiram effects on cytochrome P-450 2C9, 2C19, 2D6, and 3A4 activities: evidence for specificity toward P-450 2E1.
    Kharasch ED; Hankins DC; Jubert C; Thummel KE; Taraday JK
    Drug Metab Dispos; 1999 Jun; 27(6):717-23. PubMed ID: 10348802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics and pharmacogenomics.
    Leeder JS
    Pediatr Clin North Am; 2001 Jun; 48(3):765-81. PubMed ID: 11411304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative analysis of constitutive and inducible CYPs mRNA expression in the HepG2 cell line using reverse transcription-competitive PCR.
    Sumida A; Fukuen S; Yamamoto I; Matsuda H; Naohara M; Azuma J
    Biochem Biophys Res Commun; 2000 Jan; 267(3):756-60. PubMed ID: 10673364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human cytochrome P450s: selectivity and measurement in vivo.
    Smith DA; Abel SM; Hyland R; Jones BC
    Xenobiotica; 1998 Dec; 28(12):1095-128. PubMed ID: 9890156
    [No Abstract]   [Full Text] [Related]  

  • 12. Human liver cytochrome P-450 and conjugating enzymes. Hungarian data.
    Vereczkey L; Jemnitz K; Monostory K
    Acta Physiol Hung; 1997-1998; 85(2):149-52. PubMed ID: 9706309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Status of pharmacogenomics and its future role in drug therapy].
    Cascorbi I
    Internist (Berl); 2002 Apr; 43(4):506-10. PubMed ID: 12053407
    [No Abstract]   [Full Text] [Related]  

  • 14. Phenotyping of drug metabolism in infants and children: potentials and problems.
    Rane A
    Pediatrics; 1999 Sep; 104(3 Pt 2):640-3. PubMed ID: 10469807
    [No Abstract]   [Full Text] [Related]  

  • 15. Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen.
    Koenigs LL; Peter RM; Thompson SJ; Rettie AE; Trager WF
    Drug Metab Dispos; 1997 Dec; 25(12):1407-15. PubMed ID: 9394031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I and phase II drug-metabolizing enzymes are expressed and heterogeneously distributed in the biliary epithelium.
    Lakehal F; Wendum D; Barbu V; Becquemont L; Poupon R; Balladur P; Hannoun L; Ballet F; Beaune PH; Housset C
    Hepatology; 1999 Dec; 30(6):1498-506. PubMed ID: 10573530
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances: the cytochrome P450 enzymes.
    Slaughter RL; Edwards DJ
    Ann Pharmacother; 1995 Jun; 29(6):619-24. PubMed ID: 7663035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic polymorphisms of cytochrome P450 in patients with hepatitis C virus-associated hepatocellular carcinoma.
    Mochizuki J; Murakami S; Sanjo A; Takagi I; Akizuki S; Ohnishi A
    J Gastroenterol Hepatol; 2005 Aug; 20(8):1191-7. PubMed ID: 16048566
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Individualization of drug therapy and pharmacogenetics].
    Yamamoto I; Azuma J
    Nihon Rinsho; 1998 Mar; 56(3):579-83. PubMed ID: 9549339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Populations and genetic polymorphisms.
    Weber WW
    Mol Diagn; 1999 Dec; 4(4):299-307. PubMed ID: 10671640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.